-

Mirum Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Jefferies 2020 Healthcare Conference on June 2, 2020 at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.

A live audio webcast and archive of the presentation will be available in the Investors & Media section of the company website at ir.mirumpharma.com.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For more information, visit mirumpharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.

Contacts

Investor contact:
Ian Clements, Ph.D.
ir@mirumpharma.com

Media contact:
Erin Murphy
media@mirumpharma.com

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Release Summary
Mirum Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
Release Versions

Contacts

Investor contact:
Ian Clements, Ph.D.
ir@mirumpharma.com

Media contact:
Erin Murphy
media@mirumpharma.com

More News From Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

TORONTO--(BUSINESS WIRE)--Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Alagille Syndrome...

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

TORONTO--(BUSINESS WIRE)--Health Canada Authorizes Mirum's LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis...

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease...
Back to Newsroom